Clinical Trial Update: An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143g [Phase 3]

View source ↗

Summary

This update describes an extension Phase 3 study of Xolair (omalizumab) in patients with moderate to severe persistent asthma who completed Study Q2143g; the ex…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Asthma | Phase 3 | Status: COMPLETED